X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs FRESENIUS KABI ONCO. - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA FRESENIUS KABI ONCO. ABBOTT INDIA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 36.7 22.1 166.0% View Chart
P/BV x 9.5 3.1 303.6% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ABBOTT INDIA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
FRESENIUS KABI ONCO.
Mar-13
ABBOTT INDIA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs6,110176 3,471.6%   
Low Rs3,99679 5,090.4%   
Sales per share (Unadj.) Rs1,552.237.7 4,118.9%  
Earnings per share (Unadj.) Rs188.85.1 3,707.0%  
Cash flow per share (Unadj.) Rs196.46.7 2,921.6%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.642.5 1,872.4%  
Shares outstanding (eoy) m21.25158.23 13.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.33.4 96.4%   
Avg P/E ratio x26.825.0 107.1%  
P/CF ratio (eoy) x25.718.9 135.9%  
Price / Book Value ratio x6.33.0 212.1%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,37620,135 533.3%   
No. of employees `0003.31.2 288.4%   
Total wages/salary Rs m3,937703 559.9%   
Avg. sales/employee Rs Th9,929.35,176.2 191.8%   
Avg. wages/employee Rs Th1,185.1610.4 194.1%   
Avg. net profit/employee Rs Th1,207.7699.6 172.6%   
INCOME DATA
Net Sales Rs m32,9855,963 553.2%  
Other income Rs m1,17018 6,499.4%   
Total revenues Rs m34,1555,981 571.1%   
Gross profit Rs m5,2451,430 366.8%  
Depreciation Rs m162258 62.8%   
Interest Rs m38-26 -146.9%   
Profit before tax Rs m6,2151,216 511.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m2,203342 643.7%   
Profit after tax Rs m4,012806 497.8%  
Gross profit margin %15.924.0 66.3%  
Effective tax rate %35.428.1 126.0%   
Net profit margin %12.213.5 90.0%  
BALANCE SHEET DATA
Current assets Rs m22,6555,102 444.1%   
Current liabilities Rs m6,6812,385 280.1%   
Net working cap to sales %48.445.6 106.3%  
Current ratio x3.42.1 158.6%  
Inventory Days Days65150 43.2%  
Debtors Days Days29113 25.7%  
Net fixed assets Rs m8355,148 16.2%   
Share capital Rs m213158 134.3%   
"Free" reserves Rs m16,7156,556 255.0%   
Net worth Rs m16,9286,732 251.5%   
Long term debt Rs m0952 0.0%   
Total assets Rs m24,16210,388 232.6%  
Interest coverage x163.7-45.8 -357.6%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.40.6 237.8%   
Return on assets %16.87.5 223.3%  
Return on equity %23.712.0 198.0%  
Return on capital %36.914.6 253.0%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m3695,298 7.0%   
Fx outflow Rs m3,8071,772 214.8%   
Net fx Rs m-3,4383,525 -97.5%   
CASH FLOW
From Operations Rs m1,5271,274 119.8%  
From Investments Rs m-2,148-1,204 178.4%  
From Financial Activity Rs m-1,024-196 522.3%  
Net Cashflow Rs m-1,646-126 1,302.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 7.9 0.3 2,633.3%  
FIIs % 0.1 9.6 1.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 9.1 187.9%  
Shareholders   18,270 42,599 42.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  BIOCON LTD  J.B.CHEMICALS  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Dec 14, 2018 03:35 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - CADILA HEALTHCARE COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS